The firm is an impact-oriented venture capital investor focused on advancing innovative healthcare technologies with significant clinical and commercial potential. The firm is developing a dedicated healthcare investment fund targeting approximately $150M in commitments and primarily invests at the Series A stage. The firm deploys equity capital to support companies approaching important clinical, regulatory, or commercial milestones. The firm primarily targets opportunities in the United States, with selective interest in Europe and Israel.
The firm focuses on oncology therapeutics, cardiovascular medical devices, and other differentiated healthcare innovations. Within oncology, the firm is modality-agnostic and evaluates novel therapeutic approaches with strong scientific rationale and clearly defined development pathways. The firm generally prefers therapeutic programs approaching IND clearance or entering early clinical development. Within medical devices, the firm has a particular interest in cardiovascular technologies and prioritizes FDA-regulated products requiring Premarket Approval (PMA), while remaining open to select 510(k) devices. Medical device companies are generally expected to have a functional prototype. The firm may also consider opportunities outside its core sectors when technologies demonstrate exceptional innovation and substantial growth potential.
From a company and management team perspective, the firm seeks experienced leadership teams capable of executing clinical development, regulatory, and commercialization strategies. The firm prioritizes strong scientific foundations, credible development plans, and clear pathways toward meaningful patient impact. The firm takes an engaged investment approach and supports portfolio companies through strategic guidance, governance participation, and access to clinical, regulatory, and industry networks.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
